CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT) promoter region, which confers a limited response to standard-of-care treatment with temozolomide (TMZ), resulting in shorter median survival when compared to patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Chen, Zhong-ping, Guo, Cheng-Cheng, Yang, Qun-ying, Wu, Shao-xiong, Li, Jia-Wei, Bacha, Jeffrey, Johnson, Greg, Langlands, John, Schwartz, Richard, Kwan, Claire, Kanekal, Sarath, Steino, Anne, Lopez, Lorena, Brown, Dennis
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651087/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.242
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados